Journal: BMC Cancer

Article Title: CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma

doi: 10.1186/s12885-015-1951-0

Figure Lengend Snippet: Cancer pathway-related and apoptosis-related genes significantly altered in Caki-1

Article Snippet: The target genes and their Assay ID were as follows: CYP1B1 (HSpp16383_m1), DKC1 (Hs00154737_m1), OCLN (Hs00170162_m1), FASLG (Hs00181225_m1), MKI67 (Hs01032443_m1), LPL (Hs00173425_m1), CA9 (Hs00154208_m1), CDC20 (Hs00426680_mH), TP73 (Hs00390315_m1), BCL2A1 (Hs00187845_m1), LTA (Hs04188773_g1), DAPK1 (Hs00234489_m1), BIRC5 (Hs04194391_sH) and GAPDH (Hs03929097_g1).

Techniques:

Journal: BMC Cancer

Article Title: CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma

doi: 10.1186/s12885-015-1951-0

Figure Lengend Snippet: Verification of cDNA microarray data by RT-PCR and Western blotting. a Among 9 down-regulated genes, 6 genes ( DKC1 , OCLN , MIK67 , LIG4 , CDC20 , BIRC5 ) were confirmed by real-time PCR using Taqman probe in Caki-1 cells. Of these 6 genes, CDC20 was down-regulated in both Caki-1 and 769-P cells. *, P < 0.05. **, P < 0.01.***, P < 0.001. b Among 4 up-regulated genes, TP73 and DAPK1 were confirmed by real-time PCR and only DAPK1 was down-regulated in both cell lines. *, P < 0.05. (C). Western immunoblotting analysis of DAPK1, LIG4 and CDC20 in control and CYP1B1 transfected Caki-1 and 769-P cells. A positive correlation was found between protein levels and mRNA expression of DAPK1 and CDC20 in both cell lines. GAPDH was used as a loading control

Article Snippet: The target genes and their Assay ID were as follows: CYP1B1 (HSpp16383_m1), DKC1 (Hs00154737_m1), OCLN (Hs00170162_m1), FASLG (Hs00181225_m1), MKI67 (Hs01032443_m1), LPL (Hs00173425_m1), CA9 (Hs00154208_m1), CDC20 (Hs00426680_mH), TP73 (Hs00390315_m1), BCL2A1 (Hs00187845_m1), LTA (Hs04188773_g1), DAPK1 (Hs00234489_m1), BIRC5 (Hs04194391_sH) and GAPDH (Hs03929097_g1).

Techniques: Microarray, Reverse Transcription Polymerase Chain Reaction, Western Blot, Real-time Polymerase Chain Reaction, Control, Transfection, Expressing

Journal: British Journal of Cancer

Article Title: DKC1 overexpression associated with prostate cancer progression

doi: 10.1038/sj.bjc.6605299

Figure Lengend Snippet: Expression of DKC1 in prostate cancer cell lines. ( A ) Expression of DKC1 relative to the reference gene TBP in the indicated prostate cancer cell lines and normal prostate epithelial cells (PrECs), according to quantitative RT–PCR. DKC1 and TBP were each measured in triplicate, s.e.m. are indicated. ( B ) Western blot analysis of the dyskerin protein in nuclear extracts of the indicated prostate cell lines and normal PrECs. Equal amounts of nuclear extract from each cell line were loaded and analysed for dyskerin as described in Materials and Methods.

Article Snippet: Thereafter, membranes were incubated overnight with rabbit polyclonal anti-dyskerin antibody (1 : 3000, Atlas Antibodies, Stockholm, Sweden) and mouse monoclonal anti-TBP (1 : 2000; Abcam, Cambridge, UK) as a loading control at 4°C.

Techniques: Expressing, Quantitative RT-PCR, Western Blot

Journal: British Journal of Cancer

Article Title: DKC1 overexpression associated with prostate cancer progression

doi: 10.1038/sj.bjc.6605299

Figure Lengend Snippet: Effect of DKC1 knockdown in prostate cancer cell lines. ( A ) Western blot analysis of dyskerin expression in Du145 and 22Rv1 after siRNA treatment. Top: total cell extracts; bottom: nuclear extracts; + and − symbols denote cells transfected with DKC1 siRNA and nontargeting siRNA, respectively; the slash symbol denotes untransfected cells. ( B ) Effect of siRNA on ATP amounts as an indicator of vital cell numbers after 3 days of treatment with siRNA directed against DKC1 or nontargeting siRNA (control). P -values were determined by t -test.

Article Snippet: Thereafter, membranes were incubated overnight with rabbit polyclonal anti-dyskerin antibody (1 : 3000, Atlas Antibodies, Stockholm, Sweden) and mouse monoclonal anti-TBP (1 : 2000; Abcam, Cambridge, UK) as a loading control at 4°C.

Techniques: Knockdown, Western Blot, Expressing, Transfection, Control

Journal: Frontiers in Cell and Developmental Biology

Article Title: Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma

doi: 10.3389/fcell.2025.1592135

Figure Lengend Snippet: DKC1 expression is upregulated in UCEC tumors (A) The flow chart of the study (B) The levels of DKC1 mRNA [log2 (TPM+1)] were evaluated and compared between 545 tumors and 35 non-tumorous endometrial tissues in the TCGA UCEC cohort (C) The DKC1 protein levels (Z-value) were evaluated and compared between 100 tumors and 31 non-tumorous endometrial tissues in the CPTCA UCEC cohort (D) The significantly positive correlation between mRNA and protein levels of DKC1 (Z-value) based on (B) and (C) results (E–G) The upregulation of DKC1 expression in UCEC tumors from the Qilu cohort, as determined using immunohistochemistry (IHC). The representative IHC images in (E) showed stronger DKC1 staining in tumors than in adjacent normal glands. Magnifications: ×40 (F) Comparison of IHC scores between tumors and adjacent normal glands in 12 paired samples (G) Comparison of IHC scores in all 30 tumors with 12 normal gland-containing samples.

Article Snippet: Slides were blocked using 10% goat serum and incubated with a DKC1 polyclonal antibody (Cat 25420-1-AP, Proteintech, Rosemont, IL) for 2 h at room temperature.

Techniques: Expressing, Immunohistochemistry, Staining, Comparison

Journal: Frontiers in Cell and Developmental Biology

Article Title: Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma

doi: 10.3389/fcell.2025.1592135

Figure Lengend Snippet: The positive correlation between higher DKC1 expression and TERC, telomerase activity and aggressive UCEC tumors (A–F) RNA levels were assessed using log2 (TPM+1). The TCGA cohort of UCEC was analyzed (A) Upregulation of TERC expression in UCEC tumors (B) The positive correlation between DKC1 and TERC expression (C, D) The positive correlation between DKC1 and telomerase activity. Telomerase activity levels were calculated using the telomerase score (Ref. 14) and EXTEND (Ref. 41) algorithms, respectively (E) Significantly higher DKC1 expression in serous and mixed types of UCECs (F) The association between higher DKC1 expression and higher risk of recurrence (G) The association between higher DKC1 expression and higher frequency of metastasis. The GSE120490 UCEC cohort with 145 UCEC patients (100 without and 45 with metastasis) were analyzed (H) Significantly higher DKC1 expression (microarray data) in late-stage UCEC tumors from the GSE23518 cohort (with 10 early and 10 late-stage UCECs).

Article Snippet: Slides were blocked using 10% goat serum and incubated with a DKC1 polyclonal antibody (Cat 25420-1-AP, Proteintech, Rosemont, IL) for 2 h at room temperature.

Techniques: Expressing, Activity Assay, Microarray

Journal: Frontiers in Cell and Developmental Biology

Article Title: Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma

doi: 10.3389/fcell.2025.1592135

Figure Lengend Snippet: Higher DKC1 expression predicts UCEC patient survival independently. Patients in the TCGA UCEC cohort were categorized into low and high groups based DKC1 mRNA levels in their tumors (median value as the cutoff) (A, B) Association between DKC1 expression and overall and progression-free survival (OS and PFS) (C, D) Univariate and multivariate COX regression analyses of DKC1 effect on patient OS (C) Univariate and (D) Multivariate (E, F) Univariate and multivariate COX regression analyses of DKC1 effect on patient PFS (E) Univariate and (F) Multivariate (G–I) Nomogram for prediction of UCEC PFS. A total of 349 patients were analyzed by including DKC1 (high vs. low), stage (I/II vs. III/IV) and age (<60 vs. ≥60) (H) The accuracy of the nomogram to predict PFS (Prediction curve vs. observed scenario) (I) The ROC prediction of PFS. ROC showed AUC values 0.67, 0.73 and 0.71 at 1, 3 and 5 years PFS, respectively. RNA levels were calculated using log2 (TPM+1).

Article Snippet: Slides were blocked using 10% goat serum and incubated with a DKC1 polyclonal antibody (Cat 25420-1-AP, Proteintech, Rosemont, IL) for 2 h at room temperature.

Techniques: Expressing

Journal: Frontiers in Cell and Developmental Biology

Article Title: Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma

doi: 10.3389/fcell.2025.1592135

Figure Lengend Snippet: DKC1 expression is regulated by genomic alterations and female sex hormones but not by telomere length in UCEC tumors and cells. The TCGA cohort of UCEC tumors and UCEC-derived cells were analyzed (A) Differences in DKC1 expression in UCEC tumors carrying different copy numbers (B) Differences in DKC1 copy numbers between endometrial and serous/mixed types of UCEC tumors (C) The mutational landscape of the DKC1 gene in UCEC tumors (D) Up- and downregulation of DKC1 (Top panel) and MYC (Bottom panel) mRNA expression in UCEC-derived Ishikawa cells treated by 17 β-estradiol (left) and 1 nM MPA (right), respectively. *** and ****: P < 0.001 and 0.0001, respectively. Three independent experiments were performed (E) Correlation between DKC1 and estrogen receptor 1 (ESR1) (left) or PGR (right) expression (F) No correlation between DKC1 expression and the ratios of telomere length of UCEC tumors and corresponding patient blood cells. Telomere length of UCEC tumors and corresponding patient blood cells were obtained from reference Barthel FP, et al.

Article Snippet: Slides were blocked using 10% goat serum and incubated with a DKC1 polyclonal antibody (Cat 25420-1-AP, Proteintech, Rosemont, IL) for 2 h at room temperature.

Techniques: Expressing, Derivative Assay

Journal: Frontiers in Cell and Developmental Biology

Article Title: Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma

doi: 10.3389/fcell.2025.1592135

Figure Lengend Snippet: Molecular features and pathway enrichments in DKC1-high UCEC tumors. A total of 545 tumors in the TCGA UCEC cohort were analyzed. Robustly increased Ki67 expression (A) , cell cycle score (B) , Stemness score (C) and EMT score (D) in DKC1-high tumors (E) The identification of enriched E2F and MYC targets as the hallmarks in DKC1-high tumors by GSEA analysis (F) The enriched cell cycle and DNA replication pathways in DKC1-high tumors by KEGG analysis.

Article Snippet: Slides were blocked using 10% goat serum and incubated with a DKC1 polyclonal antibody (Cat 25420-1-AP, Proteintech, Rosemont, IL) for 2 h at room temperature.

Techniques: Expressing

Journal: Frontiers in Cell and Developmental Biology

Article Title: Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma

doi: 10.3389/fcell.2025.1592135

Figure Lengend Snippet: DKC1 expression is associated with UCEC molecular subtypes and genomic aberrations. A total of 545 tumors in the TCGA UCEC cohort were analyzed (A) The association between DKC1 mRNA expression and molecular subtypes of UCECs (B–F) Comparisons of genomic alterations between DKC1-low and high tumors: Aneuploidy scores (B) , mitochondrial DNA (MTDNA) copies (C) , HRD (D) , MSI (E) and TMB (F) (G) Different frequencies of genomic alterations in important UCEC driver genes between DKC1-low and high tumors.

Article Snippet: Slides were blocked using 10% goat serum and incubated with a DKC1 polyclonal antibody (Cat 25420-1-AP, Proteintech, Rosemont, IL) for 2 h at room temperature.

Techniques: Expressing

Journal: Frontiers in Cell and Developmental Biology

Article Title: Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma

doi: 10.3389/fcell.2025.1592135

Figure Lengend Snippet: Identification of defective anti-tumor immunity and immunoexclusion microenvironments in DKC1-high tumors. A total of 544 tumors in the TCGA UCEC cohort were analyzed (A) Differences in immune, stromal and estimate scores between DKC1-high and low tumors, as determined using ESTIMATE analysis (B) TIDE analyses for comparison between DKC1-high and low tumors (C) CD274, CTLA4 and VTCN1 expression in DKC1-high and low tumors (D) Cancer immune cycle analyses of DKC1-high and low tumors. *, ** and ***: P < 0.05, 0.01 and 0.001, respectively (E) Differences in MHC scores between DKC1-high and low tumors (F) Prediction of DKC1-high and low tumors to immune checkpoint inhibitor sensitivity. Higher DKC1 expression is associated with lower sensitivity to immune checkpoint inhibitors.

Article Snippet: Slides were blocked using 10% goat serum and incubated with a DKC1 polyclonal antibody (Cat 25420-1-AP, Proteintech, Rosemont, IL) for 2 h at room temperature.

Techniques: Comparison, Expressing

Journal: Molecular cell

Article Title: Systematic Discovery of RNA Binding Proteins that Regulate MicroRNA Levels

doi: 10.1016/j.molcel.2018.02.012

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Rabbit anti-DKC1 (1:1,000 for WB) , Genetex , Cat# GTX109000; RRID: AB_11165396.

Techniques: Immunoprecipitation, Recombinant, Protease Inhibitor, RNA Library Preparation, SYBR Green Assay, Northern Blot, Software